人民财讯10月23日电，力生制药（002393）10月23日披露2025年三季度报告，公司第三季度实现营业收 入2.76亿元，同比下降1.2%；归母净利润2781.64万元，同比下降58.42%。前三季度实现营业收入10.07 亿元，同比下降1.61%；归母净利润3.71亿元，同比增长119.05%。 ...

证券代码：002393 证券简称：力生制药 公告编号：2025-067 第七届监事会第四十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 天津力生制药股份有限公司(以下简称"公司"或"本公司")于2025年10月15日以书面方 式发出召开第七届监事会第四十四次会议的通知，会议于2025年10月22日以通讯表决方式 召开。会议应参加的监事3名，实际参加的监事3名，符合《公司法》及《公司章程》的规 定。 二、监事会会议审议情况 1、会议以3票同意、0票反对、0票弃权的表决结果，审议通过了《关于2025年第三 季度报告全文的议案》； 监事会的专项审查意见为：经审查，监事会认为董事会编制和审核《2025 年第三季 度报告全文》的程序符合法律、行政法规和中国证监会的相关规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 2025 年第三季度报告详见巨潮资讯网（www.cninfo.com.cn）、中国证券报和证券时 报。 2、会议以3票同意、0票反对、0票弃权的表决结果，审议通过 ...

证券代码：002393 证券简称：力生制药 公告编号：2025-063 天津力生制药股份有限公司 第七届董事会第五十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 天津力生制药股份有限公司(以下简称"公司"或"本公司")于2025年10月15日以书面方式 发出召开第七届董事会第五十三次会议的通知，会议于2025年10月22日以通讯表决方式召 开。会议应参加的董事9名，实际参加的董事9名。符合《公司法》及《公司章程》的规定。 二、董事会会议审议情况 1、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《关于2025年第三季度 报告全文的议案》； 具体公告详见巨潮资讯网（www.cninfo.com.cn）、中国证券报和证券时报。 2、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《关于选举公司第八届 董事会非独立董事的议案》； 公司第七届董事会任期即将届满，为进一步完善公司治理结构，符合有关法律法规的规 定以及相关监管要求，由公司控股股东天津金浩医药有限公司提名，经公司第七届董事会提 名委员会第八次会议 ...

Financial Performance - Q3 2025 revenue was CNY 275,772,357.58, a decrease of 1.20% year-over-year[5] - Net profit attributable to shareholders was CNY 27,816,377.14, down 58.42% compared to the same period last year[5] - The net profit excluding non-recurring gains and losses increased by 215.67% to CNY 22,500,091.96 for the quarter[5] - Total operating revenue for the current period is ¥1,007,280,440.26, a decrease of 1.5% from ¥1,023,773,647.92 in the previous period[19] - Total operating costs decreased to ¥871,042,976.72, down 3.6% from ¥903,119,117.83[19] - Operating profit increased significantly to ¥446,001,766.23, compared to ¥201,408,039.28 in the previous period, representing a growth of 121.5%[20] - Net profit for the current period reached ¥374,284,895.92, up 122.3% from ¥168,334,446.76 in the previous period[20] - Basic and diluted earnings per share improved to ¥1.44, compared to ¥0.66 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,921,182,710.88, reflecting a 2.35% increase from the end of the previous year[5] - As of September 30, 2025, the company's total assets amounted to ¥5,921,182,710.88, an increase from ¥5,785,511,812.28 at the beginning of the period[16] - Total current liabilities decreased to ¥680,470,444.16 from ¥746,527,866.55, a reduction of about 8.8%[16] - The company's total equity increased to ¥5,003,333,340.77 from ¥4,799,975,192.40, representing a growth of approximately 4.2%[17] - The company's inventory decreased to ¥209,740,616.35 from ¥224,365,964.79, a decline of about 6.5%[15] - The company's accounts receivable increased to ¥258,102,265.86 from ¥207,964,785.31, an increase of approximately 24%[15] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was CNY 124,819,596.56, an increase of 35.98%[5] - Cash flow from operating activities generated a net amount of ¥124,819,596.56, an increase from ¥91,795,856.55 in the previous period[21] - Cash flow from investment activities resulted in a net outflow of ¥350,088,014.01, slightly improved from a net outflow of ¥360,312,732.89 in the previous period[22] - The company's cash and cash equivalents decreased to ¥1,227,839,683.33 from ¥1,638,999,235.40, reflecting a decline of approximately 25.1%[15] - Cash and cash equivalents at the end of the period totaled ¥1,227,242,885.76, down from ¥1,537,434,495.00 at the end of the previous period[22] - Investment income for the period increased by 316.03% year-over-year, primarily due to dividends declared by Tianjin Tasly Biological Pharmaceutical Group[9] - The company reported a significant increase in investment income to ¥319,543,582.30, compared to ¥76,807,083.51 in the previous period[20] Borrowings and Equity - Short-term borrowings decreased by 37.17% compared to the beginning of the year, indicating reduced loan activity[9] - The company's short-term borrowings decreased to ¥25,000,000.00 from ¥39,790,877.05, a decline of about 37.4%[16] - The company's long-term investments in other equity instruments remained stable at ¥1,294,988,767.84, showing minimal change from ¥1,295,159,677.96[15] - The company's retained earnings increased to ¥1,736,370,355.18 from ¥1,459,524,542.12, reflecting a growth of approximately 18.9%[17] Share Repurchase - The company repurchased 1,439,980 shares as of September 30, 2025[12] Audit Status - The company has not undergone an audit for the third quarter financial report[23]

（文章来源：证券日报） 证券日报网讯力生制药10月21日在互动平台回答投资者提问时表示，截至2025年10月20日，公司股东户 数为23887户。 ...

Market Overview - On October 17, the Tianjin state-owned enterprise reform sector fell by 2.19% compared to the previous trading day, with Baili Electric leading the decline [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Key stocks in the Tianjin state-owned enterprise reform sector showed mixed performance, with Guifaxiang rising by 4.13% to a closing price of 12.86, while Baili Electric dropped by 6.69% to 6.56 [2] - The trading volume and turnover for Guifaxiang were 263,400 shares and 337 million yuan, respectively [2] Capital Flow - The main funds in the Tianjin state-owned enterprise reform sector experienced a net outflow of 180 million yuan, while retail investors saw a net inflow of 204 million yuan [2][3] - The capital flow data indicates that Guifaxiang had a net inflow of 28.86 million yuan from main funds, while Tianjin Port saw a net outflow of 4.73 million yuan [3]

（文章来源：证券日报） 证券日报网讯力生制药10月13日在互动平台回答投资者提问时表示，截至2025年9月30日公司股东户数 为23856户。 ...

Market Overview - On September 25, the Tianjin state-owned enterprise reform sector fell by 0.72% compared to the previous trading day, with Jintou Chengkai leading the decline [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - The following stocks in the Tianjin state-owned enterprise reform sector showed notable performance: - Baili Electric (600468) closed at 6.73, up 4.02% with a trading volume of 1.021 million shares and a turnover of 693 million yuan [1] - Jintou Chengkai (600322) closed at 2.35, down 6.37% with a trading volume of 868,900 shares and a turnover of 210 million yuan [2] - Other stocks such as Tianjin Port (600717) and Taida Co. (000652) also experienced declines of 1.28% and 1.45% respectively [1][2] Capital Flow Analysis - The Tianjin state-owned enterprise reform sector saw a net outflow of 38.27 million yuan from main funds, while speculative funds had a net inflow of 53.41 million yuan, and retail investors experienced a net outflow of 15.13 million yuan [2] - Specific stock capital flows included: - Baili Electric had a net inflow of 20.84 million yuan from main funds, while retail investors saw a net outflow of 4.25 million yuan [3] - Tianjin Port had a net inflow of 9.34 million yuan from speculative funds, but a net outflow of 9.81 million yuan from retail investors [3]

Core Viewpoint - The company, Lisheng Pharmaceutical, reported that as of September 10, 2025, the number of shareholders is 25,376 [1] Summary by Categories - **Company Information** - Lisheng Pharmaceutical has a total of 25,376 shareholders as of the specified date [1]

Group 1 - The company, Lisheng Pharmaceutical (002393.SZ), currently has no drugs available for the treatment of the specified disease [1]